Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Genes|August 26, 2022
Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q QuestionnaireNatalie Herold, Martin Hellmich, Frank Lichtenheldt, et al.
Anticancer Research|September 12, 2013
PTK7 expression in triple-negative breast cancerBeyhan Ataseven, Regina Angerer, Ronald Kates, et al.
BMC Cancer|April 20, 2013
Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activatorPhilip Vlaicu, Philipp Mertins, Thomas Mayr, et al.
Plos One|January 11, 2014
PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvementSilvia Gärtner, Angela Gunesch, Tatiana Knyazeva, et al.
Geburtshilfe Und Frauenheilkunde|October 27, 2018
Low-grade Serous Ovarian CarcinomaEnzo Ricciardi, Thaïs Baert, Beyhan Ataseven, et al.
Gynecologic Oncology|November 20, 2016
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancerFlorian Heitz, Alexandra Hengsbach, Philipp Harter, et al.
Gynecologic Oncology|July 13, 2015
Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgeryBeyhan Ataseven, Andreas du Bois, Alexander Reinthaller, et al.
Gynecologic Oncology|May 22, 2016
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?Beyhan Ataseven, Philipp Harter, Christoph Grimm, et al.
Annals of Surgical Oncology|April 11, 2018
Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic LymphadenectomyFlorian Heitz, Philipp Harter, Beyhan Ataseven, et al.
Therapeutic Advances in Medical Oncology|October 4, 2023
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in GermanyMattea Reinisch, Simona Bruzas, Jennifer Spoenlein, et al.
Pageof 11